-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Pardes Biosciences (NASDAQ:PRDS) Coverage Initiated by Analysts at JMP Securities
Pardes Biosciences (NASDAQ:PRDS) Coverage Initiated by Analysts at JMP Securities
JMP Securities initiated coverage on shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a market outperform rating and a $9.00 price objective on the stock.
Separately, SVB Leerink cut their price target on shares of Pardes Biosciences from $18.00 to $12.00 and set an outperform rating for the company in a research note on Tuesday, August 16th.
Get Pardes Biosciences alerts:Pardes Biosciences Trading Up 3.5 %
NASDAQ PRDS opened at $1.19 on Tuesday. The firm has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $2.62. Pardes Biosciences has a twelve month low of $0.75 and a twelve month high of $17.76.
Pardes Biosciences (NASDAQ:PRDS – Get Rating) last announced its quarterly earnings results on Monday, November 7th. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.09. As a group, sell-side analysts expect that Pardes Biosciences will post -1.77 earnings per share for the current fiscal year.Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRDS. RA Capital Management L.P. increased its holdings in shares of Pardes Biosciences by 97.5% during the first quarter. RA Capital Management L.P. now owns 6,175,038 shares of the company's stock worth $44,584,000 after buying an additional 3,048,000 shares in the last quarter. VK Services LLC acquired a new stake in shares of Pardes Biosciences during the second quarter worth approximately $18,886,000. Goldman Sachs Group Inc. increased its holdings in shares of Pardes Biosciences by 102.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,275,914 shares of the company's stock worth $13,127,000 after buying an additional 2,163,503 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Pardes Biosciences by 4.4% during the third quarter. Lynx1 Capital Management LP now owns 2,275,732 shares of the company's stock worth $4,210,000 after buying an additional 95,172 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Pardes Biosciences during the first quarter worth approximately $15,025,000. Institutional investors own 75.06% of the company's stock.
Pardes Biosciences Company Profile
(Get Rating)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
JMP Securities initiated coverage on shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) in a research report sent to investors on Tuesday, The Fly reports. The firm issued a market outperform rating and a $9.00 price objective on the stock.
據The Fly報道，JMP證券在週二發給投資者的一份研究報告中啟動了對Pardes Biosciences(納斯達克：PRDS-GET評級)股票的報道。該公司對該股發佈了表現優於市場的評級和9.00美元的目標價。
Separately, SVB Leerink cut their price target on shares of Pardes Biosciences from $18.00 to $12.00 and set an outperform rating for the company in a research note on Tuesday, August 16th.
另外，SVB Leerink在8月16日週二的一份研究報告中將Pardes Biosciences的目標價從18.00美元下調至12.00美元，並為該公司設定了表現優於大盤的評級。
Pardes Biosciences Trading Up 3.5 %
Pardes Biosciences股價上漲3.5%
NASDAQ PRDS opened at $1.19 on Tuesday. The firm has a 50-day simple moving average of $1.23 and a 200 day simple moving average of $2.62. Pardes Biosciences has a twelve month low of $0.75 and a twelve month high of $17.76.
納斯達克PRDS週二開盤報1.19美元。該公司的50日簡單移動均線切入位在1.23美元，200日簡單移動均線切入位在2.62美元。Pardes Biosciences的12個月低點為0.75美元，12個月高位為17.76美元。
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PRDS. RA Capital Management L.P. increased its holdings in shares of Pardes Biosciences by 97.5% during the first quarter. RA Capital Management L.P. now owns 6,175,038 shares of the company's stock worth $44,584,000 after buying an additional 3,048,000 shares in the last quarter. VK Services LLC acquired a new stake in shares of Pardes Biosciences during the second quarter worth approximately $18,886,000. Goldman Sachs Group Inc. increased its holdings in shares of Pardes Biosciences by 102.4% during the second quarter. Goldman Sachs Group Inc. now owns 4,275,914 shares of the company's stock worth $13,127,000 after buying an additional 2,163,503 shares in the last quarter. Lynx1 Capital Management LP increased its holdings in shares of Pardes Biosciences by 4.4% during the third quarter. Lynx1 Capital Management LP now owns 2,275,732 shares of the company's stock worth $4,210,000 after buying an additional 95,172 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new stake in shares of Pardes Biosciences during the first quarter worth approximately $15,025,000. Institutional investors own 75.06% of the company's stock.
一些對沖基金和其他機構投資者最近增持或減持了PRDS的股份。Ra Capital Management L.P.在第一季度增持了Pardes Biosciences的股票97.5%。Ra Capital Management L.P.現在持有該公司6,175,038股股票，價值44,584,000美元，上個季度又購買了3,048,000股。VK Services LLC在第二季度收購了Pardes Biosciences的新股份，價值約18,886,000美元。高盛股份有限公司在第二季度增持了帕德斯生物科學公司的股票102.4%。高盛股份有限公司現在持有該公司4,275,914股股票，價值13,127,000美元，該公司在上個季度又購買了2,163,503股。Lynx1 Capital Management LP在第三季度增持了Pardes Biosciences的股票4.4%。Lynx1 Capital Management LP在上個季度額外購買了95,172股後，現在擁有2,275,732股該公司股票，價值4,210,000美元。最後，弗雷澤生命科學管理公司在第一季度收購了帕德斯生物科學公司價值約15,025,000美元的新股份。機構投資者持有該公司75.06%的股份。
Pardes Biosciences Company Profile
Pardes Biosciences公司簡介
(Get Rating)
(獲取評級)
Pardes Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases.
Pardes Biosciences，Inc.是一家臨床階段的生物製藥公司，專注於發現、開發和商業化新的治療方法，以改善威脅生命的疾病患者的生活。它的主要候選藥物是處於臨床開發階段的PBI-0451，用於治療和預防嚴重急性呼吸綜合徵冠狀病毒2型感染和相關疾病。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Pardes Biosciences (PRDS)
- We Are the Champions: 3 Dividend Growers Wall Street Loves
- Will Nordstrom Stock be the Grinch This Year?
- Harpoon Therapeutics Remains Volatile After Promising News
- What is Market Structure in Trading?
- Institutional Selling Is No Headwind For Nike
- 免費獲取StockNews.com關於Pardes Biosciences的研究報告(PRDS)
- 我們是冠軍：華爾街鍾愛的3位股息種植者
- 諾德斯特龍股票公司會成為今年的格林奇嗎？
- 魚叉治療公司在有希望的消息傳出後仍不穩定
- 交易中的市場結構是什麼？
- 機構銷售對耐克來說不是逆風
Receive News & Ratings for Pardes Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pardes Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受帕德斯生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Pardes Biosciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧